Cardiol Therapeutics Inc (CRDL) News & EventsCRDLCardiol Therapeutics Inc

Cardiol Therapeutics Enters $75M Sales Agreement with Jefferies

Cardiol Therapeutics is pleased to announce that it has entered into a sales agreement with Jefferies for an at-the-market offering program. The ATM Agreement will allow the company to offer and sell up to $75M of common shares of the company under the ATM Program. The Offered Shares may be offered and sold by the company to the public from time to time, through the Sales Agent. The Offered Shares sold under the ATM Program, if any, will be sold by means of ordinary brokers' transactions on the Nasdaq Capital Market or any other trading markets for the common shares in the United States at the prevailing market prices at the time of the sale. No Offered Shares will be offered or sold through the Toronto Stock Exchange or otherwise in Canada.

Cardiol Therapeutics Announces Enrollment Progress in MAVERIC Trial

Cardiol Therapeutics announced enrollment progress and plans to expand MAVERIC, the Company's pivotal Phase III randomized, double-blind, placebo-controlled, multi-center trial evaluating CardiolRx for the reduction in risk of recurrence in patients with recurrent pericarditis. As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance. "A blinded review of events in MAVERIC patients who have been randomized 1:1 to either CardiolRx or placebo shows a lower level of pericarditis recurrence than anticipated, an observation we view as encouraging, particularly as we are not aware of changes in routine clinical practice that would explain this finding," said David Elsley, CEO. "Our planned enrollment expansion is designed to support the event count needed to preserve the trial's planned statistical power and deliver a more robust assessment of CardiolRx's efficacy. Topline results are now anticipated in mid-2027, compared with our previous Q1 2027 guidance. With our cash runway extending into Q1 2028, we are in a strong position to complete MAVERIC and deliver this important clinical readout."

Cardiol Therapeutics Files $150M Financing Application

Cardiol Therapeutics announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 with the United States SEC under the U.S./Canada Multijurisdictional Disclosure System. Once a receipt has been issued for the final short form base shelf prospectus and the Registration Statement has become effective, the filings will permit Cardiol to offer and sell, from time to time during the 25-month period the final short form base shelf prospectus remains effective, Class A common shares, debt securities, warrants, subscription receipts, units, or any combination of such securities, having an aggregate initial offering price of up to $150M, or the equivalent in other currencies.